PPP02 演讲时间：上午 10:39

IF 1.7 4区医学 Q4 ONCOLOGY

Brachytherapy Pub Date : 2024-10-25 DOI:10.1016/j.brachy.2024.08.094

Irini Youssef MD, Rahul Barve MD, Victoria Brennan MD, Daniel Gorovets MD, Daniel Shasha MD, Sankalp Pandya BSc, MRes, Joel Beaudry MS, Antonio Damato PhD, Marisa Kollmeier MD

{"title":"PPP02 演讲时间：上午 10:39","authors":"Irini Youssef MD, Rahul Barve MD, Victoria Brennan MD, Daniel Gorovets MD, Daniel Shasha MD, Sankalp Pandya BSc, MRes, Joel Beaudry MS, Antonio Damato PhD, Marisa Kollmeier MD","doi":"10.1016/j.brachy.2024.08.094","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Erectile function is a significant quality of life consideration for patients electing definitive radiation therapy. We compared erectile outcomes following low dose rate (LDR) relative to stereotactic body radiation therapy (SBRT) as monotherapy for patients with localized prostate cancer.</div></div><div><h3>Methods/Materials</h3><div>Using a prospectively collected institutional database, we retrospectively analyzed the charts of patients who underwent LDR (I-125; 144Gy or Pd-103; 125Gy) brachytherapy or SBRT as monotherapy for prostate cancer and were potent (IIEF-5>20) at baseline. Patient-reported erectile function was measured at baseline at each post-treatment followup using IIEF-5 (International Index of Erectile Function). The use of erectile medications was also collected at each timepoint. Clinical (smoking history (none vs former/current), hypertension(yes/no) diabetes (yes/no) and dosimetric parameters were also collected.</div></div><div><h3>Results</h3><div>The study cohort included 112 patients undergoing LDR and 171 patients undergoing SBRT with a median followup of 31 months for both cohorts. Mean D90% for brachytherapy patients was 111.4%. Median SBRT dose was 4000 (range 3750-4500). 92% of patients received 4000 cGy. Mean age for SBRT patients is 66.7 years (SD±6.8) and 60.5 (SD±71) for brachytherapy patients (p<.001). There were no significant difference in smoking status (p=0.317), hypertension (p= 43) or diabetes (p= 0.18) between cohorts. There was no difference between cohorts with respect to mean baseline IIEF (27; range (21-30) (p=0.8). Mean IIEF at 12 mo ±3 was 20.6 for SBRT group versus 24.1 for brachytherapy group (P=.007). At 18 mo±3 mo, it was 20.35 for SBRT group versus 23.28 for brachytherapy group (P=.03). At 24 mo±3mo, it was 20.2 for the SBRT group versus 25.9 for the brachytherapy group (P<.001). 63% (N=107) versus 72% (N=79) patients in the SBRT and brachytherapy group, respectively, were on ED medications following treatment (P=.07).</div></div><div><h3>Conclusion</h3><div>Overall erectile preservation with IIEF >20 is high with both LDR and SBRT monotherapy. Higher mean IIEF scores were noted at multiple timepoints for LDR compared with SBRT. Further analyses are needed to assess whether these differences are clinically meaningful.</div></div>","PeriodicalId":55334,"journal":{"name":"Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PPP02 Presentation Time: 10:39 AM\",\"authors\":\"Irini Youssef MD, Rahul Barve MD, Victoria Brennan MD, Daniel Gorovets MD, Daniel Shasha MD, Sankalp Pandya BSc, MRes, Joel Beaudry MS, Antonio Damato PhD, Marisa Kollmeier MD\",\"doi\":\"10.1016/j.brachy.2024.08.094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Erectile function is a significant quality of life consideration for patients electing definitive radiation therapy. We compared erectile outcomes following low dose rate (LDR) relative to stereotactic body radiation therapy (SBRT) as monotherapy for patients with localized prostate cancer.</div></div><div><h3>Methods/Materials</h3><div>Using a prospectively collected institutional database, we retrospectively analyzed the charts of patients who underwent LDR (I-125; 144Gy or Pd-103; 125Gy) brachytherapy or SBRT as monotherapy for prostate cancer and were potent (IIEF-5>20) at baseline. Patient-reported erectile function was measured at baseline at each post-treatment followup using IIEF-5 (International Index of Erectile Function). The use of erectile medications was also collected at each timepoint. Clinical (smoking history (none vs former/current), hypertension(yes/no) diabetes (yes/no) and dosimetric parameters were also collected.</div></div><div><h3>Results</h3><div>The study cohort included 112 patients undergoing LDR and 171 patients undergoing SBRT with a median followup of 31 months for both cohorts. Mean D90% for brachytherapy patients was 111.4%. Median SBRT dose was 4000 (range 3750-4500). 92% of patients received 4000 cGy. Mean age for SBRT patients is 66.7 years (SD±6.8) and 60.5 (SD±71) for brachytherapy patients (p<.001). There were no significant difference in smoking status (p=0.317), hypertension (p= 43) or diabetes (p= 0.18) between cohorts. There was no difference between cohorts with respect to mean baseline IIEF (27; range (21-30) (p=0.8). Mean IIEF at 12 mo ±3 was 20.6 for SBRT group versus 24.1 for brachytherapy group (P=.007). At 18 mo±3 mo, it was 20.35 for SBRT group versus 23.28 for brachytherapy group (P=.03). At 24 mo±3mo, it was 20.2 for the SBRT group versus 25.9 for the brachytherapy group (P<.001). 63% (N=107) versus 72% (N=79) patients in the SBRT and brachytherapy group, respectively, were on ED medications following treatment (P=.07).</div></div><div><h3>Conclusion</h3><div>Overall erectile preservation with IIEF >20 is high with both LDR and SBRT monotherapy. Higher mean IIEF scores were noted at multiple timepoints for LDR compared with SBRT. Further analyses are needed to assess whether these differences are clinically meaningful.</div></div>\",\"PeriodicalId\":55334,\"journal\":{\"name\":\"Brachytherapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brachytherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1538472124002307\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brachytherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538472124002307","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的勃起功能是选择确定性放射治疗患者生活质量的一个重要考虑因素。我们比较了局部前列腺癌患者接受低剂量率（LDR）和立体定向体放射治疗（SBRT）作为单一疗法后的勃起功能结果。方法/材料利用前瞻性收集的机构数据库，我们回顾性分析了接受 LDR（I-125；144Gy 或 Pd-103；125Gy）近距离放射治疗或 SBRT 作为单一疗法治疗前列腺癌且基线时勃起功能良好（IIEF-5>20）的患者的病历。患者报告的勃起功能在治疗后的每次随访中使用 IIEF-5（国际勃起功能指数）进行基线测量。在每个时间点还收集了勃起药物的使用情况。此外，还收集了临床（吸烟史（无与曾经/现在）、高血压（是/否）、糖尿病（是/否））和剂量学参数。结果研究队列包括112名接受LDR治疗的患者和171名接受SBRT治疗的患者，两组患者的中位随访时间均为31个月。近距离放射治疗患者的平均 D90% 为 111.4%。中位 SBRT 剂量为 4000（范围为 3750-4500）。92%的患者接受了4000 cGy的治疗。SBRT患者的平均年龄为66.7岁（SD±6.8），近距离治疗患者的平均年龄为60.5岁（SD±71）（p<.001）。各组间的吸烟状况（p=0.317）、高血压（p= 43）或糖尿病（p= 0.18）无明显差异。各组间基线 IIEF 平均值（27；范围（21-30））无差异（p=0.8）。12个月（±3个月）时，SBRT组的平均IIEF为20.6，近距离治疗组为24.1（P=0.007）。在 18 个月（±3 个月）时，SBRT 组的平均 IIEF 为 20.35，而近距离治疗组为 23.28（P=.03）。在 24 个月（±3 个月）时，SBRT 组为 20.2，近距离治疗组为 25.9（P< .001）。SBRT组和近距离放射治疗组分别有63%（N=107）和72%（N=79）的患者在治疗后服用ED药物（P=.07）。与 SBRT 相比，LDR 在多个时间点的平均 IIEF 分数更高。这些差异是否具有临床意义还需要进一步分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

PPP02 Presentation Time: 10:39 AM

Purpose

Erectile function is a significant quality of life consideration for patients electing definitive radiation therapy. We compared erectile outcomes following low dose rate (LDR) relative to stereotactic body radiation therapy (SBRT) as monotherapy for patients with localized prostate cancer.

Methods/Materials

Using a prospectively collected institutional database, we retrospectively analyzed the charts of patients who underwent LDR (I-125; 144Gy or Pd-103; 125Gy) brachytherapy or SBRT as monotherapy for prostate cancer and were potent (IIEF-5>20) at baseline. Patient-reported erectile function was measured at baseline at each post-treatment followup using IIEF-5 (International Index of Erectile Function). The use of erectile medications was also collected at each timepoint. Clinical (smoking history (none vs former/current), hypertension(yes/no) diabetes (yes/no) and dosimetric parameters were also collected.

Results

The study cohort included 112 patients undergoing LDR and 171 patients undergoing SBRT with a median followup of 31 months for both cohorts. Mean D90% for brachytherapy patients was 111.4%. Median SBRT dose was 4000 (range 3750-4500). 92% of patients received 4000 cGy. Mean age for SBRT patients is 66.7 years (SD±6.8) and 60.5 (SD±71) for brachytherapy patients (p<.001). There were no significant difference in smoking status (p=0.317), hypertension (p= 43) or diabetes (p= 0.18) between cohorts. There was no difference between cohorts with respect to mean baseline IIEF (27; range (21-30) (p=0.8). Mean IIEF at 12 mo ±3 was 20.6 for SBRT group versus 24.1 for brachytherapy group (P=.007). At 18 mo±3 mo, it was 20.35 for SBRT group versus 23.28 for brachytherapy group (P=.03). At 24 mo±3mo, it was 20.2 for the SBRT group versus 25.9 for the brachytherapy group (P<.001). 63% (N=107) versus 72% (N=79) patients in the SBRT and brachytherapy group, respectively, were on ED medications following treatment (P=.07).

Conclusion

Overall erectile preservation with IIEF >20 is high with both LDR and SBRT monotherapy. Higher mean IIEF scores were noted at multiple timepoints for LDR compared with SBRT. Further analyses are needed to assess whether these differences are clinically meaningful.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Brachytherapy 医学-核医学

CiteScore

3.40

自引率

21.10%

发文量

119

审稿时长

9.1 weeks

期刊介绍： Brachytherapy is an international and multidisciplinary journal that publishes original peer-reviewed articles and selected reviews on the techniques and clinical applications of interstitial and intracavitary radiation in the management of cancers. Laboratory and experimental research relevant to clinical practice is also included. Related disciplines include medical physics, medical oncology, and radiation oncology and radiology. Brachytherapy publishes technical advances, original articles, reviews, and point/counterpoint on controversial issues. Original articles that address any aspect of brachytherapy are invited. Letters to the Editor-in-Chief are encouraged.